FDA TNF drug warning


FDA News

September 4, 2008

Consumer Inquiries: 888-INFO-FDA

FDA: Manufacturers of TNF-Blocker Drugs Must Highlight Risk
of Fungal Infections

Agency invokes new authorities under FDAAA to alert patients
and prescribers to risk

The U.S. Food and Drug Administration today announced that the manufacturers of Humira, Cimzia, Enbrel, and Remicade must strengthen the existing warnings, in the Warnings and Precaution sections of the drugs' prescribing information and Medication Guides, on the risk of developing opportunistic fungal infections. Some patients with invasive fungal infections have died.

The four drugs, known as tumor necrosis factor alpha blockers (TNF-alpha blockers), which suppress the immune system, are approved to treat a variety of conditions which may include rheumatoid arthritis, juvenile idiopathic arthritis, psoriatic arthritis, plaque psoriasis, ankylosing spondylitis, and Crohn's disease.

FDA today exercised its new authority under the Food and Drug Administration Amendments Act of 2007 to require manufacturers of TNF inhibitors to make safety-related changes to prescribing information, or labeling.

"Under the FDA's new authorities, we can require safety label changes and a risk evaluation and mitigation strategy, known as REMS, when the agency becomes aware of new safety information," said Bob Rappaport, M.D., director of the Division of Anesthesia, Analgesia and Rheumatology Products, Center for Drug Evaluation and Research. "Requiring the risks to be highlighted will help health care professionals be more vigilant in watching for these adverse events, and is necessary to ensure that the benefits of
these drugs outweigh their risks."

Since the initial approval of the four TNF blockers, the prescribing information for these drugs has included information about the risk of serious infections, including fungal infections. However, based on reports reviewed by FDA, health care professionals are not consistently recognizing cases of histoplasmosis and other invasive fungal infections, leading to delays in treatment.

Patients taking TNF blockers should be aware that they are more susceptible to serious fungal infections. Those who develop a persistent fever, cough, shortness of breath, and fatigue should promptly seek medical attention. To assist in the diagnosis, those being treated with TNF blockers should tell their health care professionals where they live and what areas they have recently visited. Patients who develop a fungal infection may be advised to stop the TNF blocker until they recover.

FDA has reviewed 240 reports of histoplasmosis, an infection caused by the fungusHistoplasma capsulatum, in patients being treated with Enbrel, Humira, or Remicade. The majority of the reports involved people in the Ohio River and Mississippi River valleys (the fungus is commonly found in those areas). In at least 21 of the reports, histoplasmosis was initially not recognized by health care professionals, and antifungal treatment was delayed. Twelve of those patients died.

The FDA reviewed one reported case of histoplasmosis in a patient taking Cimzia. The FDA also has received reports of cases of coccidioidomycosis and blastomycosis, including deaths, in patients treated with TNF blockers.

TNF blocker manufacturers are required to submit safety labeling changes, including strengthened warnings and revisions to the Medication Guides to the FDA within 30 days or to provide a reason why they do not believe labeling changes are necessary.

If they do not submit new language, or if the FDA disagrees with the new language the company proposes, the Food and Drug Administration Amendments Act of 2007 provides strict timelines for resolving the labeling changes and allows the agency to issue an order directing the labeling change as deemed appropriate to address the new safety information.

Medication Guides will become part of a REMS for Humira and Remicade and are already part of a REMS for Enbrel and Cimzia. The manufacturers for all four of these drugs will also be required to educate prescribers about the risks.

For more information:

___ Blue Wave/QWK v2.12

Relevant Pages

  • FDA crawls from under rock- Claims Neurontin dangers
    ... Epilepsy drugs used by millions of people may increase the risk of suicidal ... The FDA analyzed almost 200 studies of 11 anti-seizure drugs, ... Overall, four people in the drug-treated groups committed suicide, and none ...
  • FDA Confirms Antidepressants Raise Childrens Suicide Risk
    ... FDA Confirms Antidepressants Raise Children's Suicide Risk ... past clinical trials of the widely used drugs. ...
  • shelve the cox 2 class of drugs: James Wright Therapeutics Initiative
    ... >> The FDA warned today that NAPROXEN increases heart attack risk. ... "Let's not be using the drugs while we're waiting to find out the ... >> in patients at risk of developing Alzheimer's disease. ...
  • Re: Shortage of ADHD drug Adderall seen persisting, liberals scream, "How will we drug our brats?"
    ... It's not the FDA. ... As for the shortages of other drugs -- the majority that are in short ... the result of business decisions by the pharmaceutical manufacturers. ...
  • Re: Baja clinic known for unorthodox care closed
    ... the FDA was engaged in aggressively spying on health-care providers who employed medications and approaches which were not considered "acceptable" by mainstream orthodox medicine. ... Reich may not have been what one could call a "model legal client", but the willingness of the US courts to incarcerate him, burn his books, and in general treat him like a criminal, demonstrated how far legal technicalities and procedural issues had replaced the original intent and spirit of the law. ... In the years since Reich's death, Constitutional protections against illegal seizure of property, assumed innocence-until-proven-guilt, and due process of law have been flagrantly violated and trampled into the dirt by the FDA leaders and field agents, who are increasingly teaming up with other arms of the federal bureaucracy to increase their power. ... Drug company money plays a powerful role in shaping health policy, the approval process for new patent drugs, and publishing research findings about the effectiveness or side-effects of those drugs. ...